Harvard Bioscience (HBIO) Current Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Current Leases data on file, last reported at $1.6 million in Q1 2026.

• Current Leases for Q1 2026 came in at $1.6 million, up 9.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 9.37% YoY), and the FY2025 annual result was $1.5 million, up 31.69% from the prior year.
• Current Leases improved to $1.6 million in Q1 2026 per HBIO's latest filing, from $1.5 million in the prior quarter.
• Over five years, Current Leases peaked at $2.2 million in Q1 2022 and troughed at $1.1 million in Q2 2024.
• A 5-year average of $1.7 million and a median of $1.5 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2024 and 2025: Current Leases tumbled 50.21% in 2024, then surged 37.33% in 2025.
• A 5-year view of Current Leases shows it stood at $2.1 million in 2022, then sank by 33.68% to $1.4 million in 2023, then declined by 18.22% to $1.2 million in 2024, then surged by 31.69% to $1.5 million in 2025, then climbed by 1.77% to $1.6 million in 2026.
• Business Quant data shows HBIO's Current Leases at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.